BMY logo

Bristol-Myers Squibb Company (BMY) Accounts receivable

Annual accounts receivable:

$9.01B+$130.00M(+1.46%)
December 31, 2024

Summary

  • As of today (August 5, 2025), BMY annual accounts receivable is $9.01 billion, with the most recent change of +$130.00 million (+1.46%) on December 31, 2024.
  • During the last 3 years, BMY annual accounts receivable has risen by +$1.03 billion (+12.95%).
  • BMY annual accounts receivable is now at all-time high.

Performance

1-year change

+1.46%

3-year change

+12.95%

5-year change

+39.16%

15-year change

+107.32%

BMY Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

98.2%
BMY annual accounts receivable is higher than 98.2% of companies in Healthcare sector

Range

All-time high

$9.01B
BMY annual accounts receivable is currently at an all-time high

3-year low

$7.98B
BMY annual accounts receivable is currently +12.95% above its 3-year low

Earnings dates

Last annual earnings report date

Dec 31, 2024
BMY previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
BMY next annual earnings announcement has not yet been scheduled

OtherBMYbalance sheet metrics

annual accounts payable

$3.60B
BMY annual accounts payable is $3.60 billion

annual total assets

$92.60B
BMY annual total assets is $92.60 billion

annual total liabilities

$76.22B
BMY annual total liabilities is $76.22 billion

annual cash & cash equivalents

$10.35B
BMY annual cash & cash equivalents is $10.35 billion

Quarterly accounts receivable:

$9.71B+$648.00M(+7.15%)
June 30, 2025

Summary

  • As of today (August 5, 2025), BMY quarterly accounts receivable is $9.71 billion, with the most recent change of +$648.00 million (+7.15%) on June 30, 2025.
  • Over the past year, BMY quarterly accounts receivable has dropped by -$35.00 million (-0.36%).
  • BMY quarterly accounts receivable is now -0.36% below its all-time high of $9.75 billion, reached on June 30, 2024.

Performance

3-month change

+7.15%

1-year change

-0.36%

3-year change

+28.01%

5-year change

+44.96%

BMY Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

98.03%
BMY quarterly accounts receivable is higher than 98.03% of companies in Healthcare sector

Range

All-time high

$9.75B
BMY quarterly accounts receivable is currently -0.36% below its historical high of $9.75 billion

3-year low

$7.59B
BMY quarterly accounts receivable is currently +28.01% above its 3-year low

Earnings dates

Last quarterly earnings report date

Jun 30, 2025
BMY previous earnings announcement was published on Jun 30, 2025

Next quarterly earnings report date

Oct 30, 2025
BMY next earnings announcement is scheduled for Oct 30, 2025

OtherBMYbalance sheet metrics

quarterly accounts payable

$5.43B
BMY quarterly accounts payable is $5.43 billion

quarterly total assets

$94.68B
BMY quarterly total assets is $94.68 billion

quarterly total liabilities

$77.19B
BMY quarterly total liabilities is $77.19 billion

quarterly cash & cash equivalents

$12.60B
BMY quarterly cash & cash equivalents is $12.60 billion

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

BMY Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+1.5%-0.4%
3 y3 years+12.9%+28.0%
5 y5 years+39.2%+45.0%

BMY Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+12.9%-0.4%+28.0%
5 y5-yearat high+39.2%-0.4%+45.0%
alltimeall timeat high+433.3%-0.4%+498.3%

BMY Accounts receivable History

DateAnnualQuarterly
Jun 2025
-
$9.71B(+7.1%)
Mar 2025
-
$9.06B(+0.6%)
Dec 2024
$9.01B(+1.5%)
$9.01B(-3.3%)
Sep 2024
-
$9.32B(-4.4%)
Jun 2024
-
$9.75B(+10.4%)
Mar 2024
-
$8.83B(-0.6%)
Dec 2023
$8.88B(+9.0%)
$8.88B(+5.7%)
Sep 2023
-
$8.41B(+3.5%)
Jun 2023
-
$8.13B(+3.5%)
Mar 2023
-
$7.85B(-3.6%)
Dec 2022
$8.15B(+2.2%)
$8.15B(+1.6%)
Sep 2022
-
$8.02B(+5.7%)
Jun 2022
-
$7.59B(+6.0%)
Mar 2022
-
$7.16B(-10.3%)
Dec 2021
$7.98B(+10.5%)
$7.98B(+1.3%)
Sep 2021
-
$7.88B(+2.1%)
Jun 2021
-
$7.71B(+7.3%)
Mar 2021
-
$7.19B(-0.4%)
Dec 2020
$7.22B(+11.5%)
$7.22B(+6.5%)
Sep 2020
-
$6.78B(+1.2%)
Jun 2020
-
$6.70B(-7.0%)
Mar 2020
-
$7.20B(+11.2%)
Dec 2019
$6.48B(+39.7%)
$6.48B(+51.0%)
Sep 2019
-
$4.29B(-4.8%)
Jun 2019
-
$4.50B(-2.0%)
Mar 2019
-
$4.59B(-0.9%)
Dec 2018
$4.64B(+6.6%)
$4.64B(+0.3%)
Sep 2018
-
$4.62B(+6.9%)
Jun 2018
-
$4.32B(-1.2%)
Mar 2018
-
$4.37B(+0.6%)
Dec 2017
$4.35B(+15.2%)
$4.35B(+0.3%)
Sep 2017
-
$4.33B(+2.7%)
Jun 2017
-
$4.22B(+3.3%)
Mar 2017
-
$4.08B(+8.2%)
Dec 2016
$3.77B(+28.0%)
$3.77B(-1.0%)
Sep 2016
-
$3.81B(+3.5%)
Jun 2016
-
$3.69B(+9.6%)
Mar 2016
-
$3.36B(+14.1%)
Dec 2015
$2.95B(+40.4%)
$2.95B(+8.6%)
Sep 2015
-
$2.71B(+6.7%)
Jun 2015
-
$2.54B(+13.0%)
Mar 2015
-
$2.25B(+7.1%)
Dec 2014
$2.10B(+24.3%)
$2.10B(+15.2%)
Sep 2014
-
$1.82B(+1.3%)
Jun 2014
-
$1.80B(+3.3%)
Mar 2014
-
$1.74B(+3.1%)
Dec 2013
$1.69B
$1.69B(-8.1%)
Sep 2013
-
$1.84B(-0.6%)
DateAnnualQuarterly
Jun 2013
-
$1.85B(+2.9%)
Mar 2013
-
$1.80B(+5.3%)
Dec 2012
$1.71B(-24.1%)
$1.71B(-1.5%)
Sep 2012
-
$1.73B(+6.8%)
Jun 2012
-
$1.62B(-55.1%)
Mar 2012
-
$3.61B(+60.6%)
Dec 2011
$2.25B(-46.9%)
$2.25B(+3.2%)
Sep 2011
-
$2.18B(+3.1%)
Jun 2011
-
$2.12B(+3.4%)
Mar 2011
-
$2.05B(+13.4%)
Jun 2010
-
$1.80B(-57.3%)
Sep 2008
-
$4.22B(-5.5%)
Jun 2008
-
$4.47B(-1.6%)
Mar 2008
-
$4.54B(+7.1%)
Dec 2007
$4.24B(+30.6%)
$4.24B(+14.5%)
Sep 2007
-
$3.70B(+2.0%)
Jun 2007
-
$3.63B(+7.4%)
Mar 2007
-
$3.38B(+4.1%)
Dec 2006
$3.25B(-3.9%)
$3.25B(+10.3%)
Sep 2006
-
$2.94B(-11.5%)
Jun 2006
-
$3.33B(+2.8%)
Mar 2006
-
$3.24B(-4.2%)
Dec 2005
$3.38B(-22.8%)
$3.38B(+2.2%)
Sep 2005
-
$3.31B(-0.3%)
Jun 2005
-
$3.31B(-9.1%)
Mar 2005
-
$3.65B(-16.6%)
Dec 2004
$4.37B(+19.5%)
$4.37B(+14.8%)
Sep 2004
-
$3.81B(+8.6%)
Jun 2004
-
$3.51B(+12.9%)
Mar 2004
-
$3.11B(-15.1%)
Dec 2003
$3.66B(+23.3%)
$3.66B(+2.0%)
Sep 2003
-
$3.59B(+11.7%)
Jun 2003
-
$3.21B(+0.8%)
Mar 2003
-
$3.19B(+7.4%)
Dec 2002
$2.97B(-25.7%)
$2.97B(-17.9%)
Sep 2002
-
$3.62B(+4.2%)
Jun 2002
-
$3.47B(-3.6%)
Mar 2002
-
$3.60B(-9.8%)
Dec 2001
$3.99B(+9.0%)
$3.99B(+6.8%)
Sep 2001
-
$3.74B(+5.3%)
Jun 2001
-
$3.55B(-10.0%)
Mar 2001
-
$3.95B(+7.8%)
Dec 2000
$3.66B(+11.9%)
$3.66B(-3.2%)
Sep 2000
-
$3.78B(+15.6%)
Dec 1999
$3.27B(+2.6%)
$3.27B(+2.6%)
Dec 1998
$3.19B(+7.3%)
$3.19B(+1.9%)
Sep 1998
-
$3.13B(+5.2%)
Dec 1997
$2.97B
$2.97B

FAQ

  • What is Bristol-Myers Squibb Company annual accounts receivable?
  • What is the all time high annual accounts receivable for Bristol-Myers Squibb Company?
  • What is Bristol-Myers Squibb Company annual accounts receivable year-on-year change?
  • What is Bristol-Myers Squibb Company quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Bristol-Myers Squibb Company?
  • What is Bristol-Myers Squibb Company quarterly accounts receivable year-on-year change?

What is Bristol-Myers Squibb Company annual accounts receivable?

The current annual accounts receivable of BMY is $9.01B

What is the all time high annual accounts receivable for Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company all-time high annual accounts receivable is $9.01B

What is Bristol-Myers Squibb Company annual accounts receivable year-on-year change?

Over the past year, BMY annual accounts receivable has changed by +$130.00M (+1.46%)

What is Bristol-Myers Squibb Company quarterly accounts receivable?

The current quarterly accounts receivable of BMY is $9.71B

What is the all time high quarterly accounts receivable for Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company all-time high quarterly accounts receivable is $9.75B

What is Bristol-Myers Squibb Company quarterly accounts receivable year-on-year change?

Over the past year, BMY quarterly accounts receivable has changed by -$35.00M (-0.36%)
On this page